Nanocan is the exclusive worldwide license holder of Nanoparticle Encapsulated Smart Technology (NEST™)
Read about the licensing of its NEST™ technology here.
NEST™ technology forms the foundation of Nancan's drug-delivery platform. Nanocan’s product development pipeline includes treatments for several cancer indications. Nanocan’s NEST™ drug delivery platform can be employed to sustainably deliver different drug payloads – including immunotherapy drugs, chemotherapy, and phytomedicines – precisely to disease sites or targets, with greater therapeutic efficacy and lower toxicity / side effects. This work leverages the abscopal effect, where treating a tumor at one site leads to regression of tumors elsewhere in the body.
The capabilities of Nanocan’s NEST™ formulations include:
Nanocan’s approach has the promise of treating both local and metastatic disease, reducing treatment time and cost, improving patient convenience, and increasing access to cancer treatment.
Nanocan’s NEST™ presents several advantages
over currently-available treatments, including:
Additionally, the Company’s NEST™ formulations can be employed to deliver
a variety of drug payloads, including phytomedicines, to potentially treat
certain respiratory diseases and pain.
Nanocan’s NEST™ products will be available in three distinct formulations optimized for treatment of specific cancer indications:
NEST™ SEEDS are implanted in tumors that are difficult to access or
are highly concentrated, such as:
NEST™ GEL can be applied to larger, superficial areas and is optimized for the following cancer indications:
NEST™ Inhalation formulation enables access to hard to target cancer indications such as: